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Hyaline Fibromatosis Syndrome (HFS) is a rare auto-
somal recessive disorder affecting primarily skin and 
mucous membranes. Skin appears thickened with subcu-
taneous nodules, associated with swollen joint contrac-
tures, red hyperpigmentation and gingival hyperplasia. 
Additional findings include osteopenia and osteoporosis, 
and the affected children are susceptible to infections 
and protein losing enteropathy (1). Histopathology of 
skin lesions shows proliferation of spindle-shaped cells, 
embedded in a homogeneous hyaline-like material, and 
biochemical alterations in type I and VI collagens as 
well as in glycosaminoglycans have been reported (2, 3).
Initially, infantile systemic hyalinosis and juvenile 
systemic hyalinosis were considered as two distinct en-
tities on the basis of time of onset. However, subsequent 
work demonstrated that both forms of hyalinosis were 
caused by mutations in the CMG2 gene (also known as 
ANTXR2), indicating that these disorders are allelic and 
part of the same phenotypic spectrum, now known as 
HFS (4, 5). 
The CMG2 gene encodes a 55-kDa type I transmem-
brane protein known as capillary morphogenesis protein 
2. While the precise physiologic function of this protein 
is currently unknown, its expression is upregulated in 
endothelial cells during capillary formation. This protein 
also serves as the main receptor of the anthrax toxin 
(6). The gene is expressed in all tissues with exception 
of the brain, a finding consistent with normal cognitive 
development of the affected individuals (6, 7).
CASE REPORTS
This study examines 4 cases with clinical features of HFS, all 
resulting from consanguineous marriages (Fig. 1 and Fig. S11). 
The clinical features of these patients are presented in Appendix 
S11. Following acquisition of informed consent in accordance with 
the Declaration of Helsinki Principles, DNA was extracted from 
peripheral blood samples taken from patients and family mem-
bers (if available) using QIAamp DNA Blood Mini Kit (Qiagen, 
Valencia, CA, USA). PCR amplification of the CMG2 gene was 
performed using 17 pairs of primers spanning all 17 exons and 
the flanking intronic sequencing, followed by bidirectional Sanger 
sequencing. For haplotype analysis and homozygosity mapping, 
additional primers were designed for typing of 13 informed SNPs 
within and flanking the CMG2 gene. 
In Family 1, DNA was not available for mutation analysis from 
the deceased proband but both parents were heterozygous car-
riers of a previously unreported splice junction mutation (c.946-
2A→G in intron 11) in CMG2, which by Human Splicing Finder 
program (www.umd.be/HSF/#) is predicted to result in aberrant 
splicing and a subsequent premature termination codon. Thus, 
the proband was deduced to be homozygous for this mutation. In 
Family 2, the proband had an insertion mutation, c.1073_1074insC 
(p.Pro358ProfsX13), which has been previously reported (8). This 
mutation in exon 13 causes a frameshift and results in premature 
termination of translation. In Family 3, a homozygous mutation, 
c.1074delT (p.Pro358ProfsX50) in exon 13, was detected; this re-
current mutation has been reported in a number of cases. In Family 
4, no mutations in the CMG2 gene were noted, and subsequent 
homozygosity mapping excluded this gene locus at chromosomal 
region 4q21 (Fig. S11).
Since the mutation c.1074delT has been encountered in a number 
of cases, we examined the possibility that this mutation is either 
a result of “founder effect” or is a “hotspot” mutation. For this 
purpose, haplotype analysis with 13 SNPs within and flanking the 
CMG2 gene was performed with DNA from the proband in Family 
2 as well as from another patient with HFS that we have recently 
described (9). The results revealed a 2 Mb conserved block within 
a 3 Mb region of the genome which included CMG2 in these pro-
bands and suggesting a founder effect in these two Iranian cases 
of different ethnicity and language group.
DISCUSSION
Thus far, 37 distinct mutations have been identified in 
CMG2 in ~150 HFS patients. This study adds a previous-
ly unreported mutation to this database. Furthermore, 
one of our patients demonstrated the same, recurrent 
mutation c.1074delT, which has previously been repor-
ted in a number of cases (9, 10). Haplotype analysis in 
the families reported here suggests that this mutation 
is a result of founder effect rather than being a hotspot 
mutation. Finally, extensive sequencing of the CMG2 
gene failed to reveal any pathogenic mutations in one 
family and homozygosity mapping excluded this gene. It 
should be noted that the latter patient had characteristic 
features of HFS, phenotypically similar to the other 4 
cases, but also had additional features not present in 
other cases examined. These include immunodeficiency 
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and infantile pyloric stenosis, features also present in 
the Jacobsen syndrome, known as 11q terminal dele-
tion syndrome (11). Identification of mutations in the 
CMG2 gene in families with HFS can be used to confirm 
clinical diagnosis and will form the basis for identifica-
tion of heterozygous carriers in extended families with 
previous history of affected children. Finally, know-
ledge of the specific mutations allows prenatal testing 
and preimplantation genetic diagnosis to prevent the 
reoccurrence of HFS in consanguineous families with 
history of this disease. 
ACKNOWLEDGEMENTS
The authors thank Sara Afsharaalam, Fatemeh 
Golnabi, and Zahra Motezaker for contributing 
to this study. Carol Kelly assisted in manuscript 
preparation, and Dr. Andrew P. South made help-
ful suggestions.
The authors declare no conflict of interest.
REFERENCES
1. Deuquet J, Lausch E, Superti-Furga A, van der 
Goot FG. The dark sides of capillary morpho-
genesis gene 2. EMBO J 2012; 31: 3–13.
2. Tanaka K, Ebihara T, Kusubata M, Adachi E, 
Arai M, Kawaguchi N, et al. Abnormal colla-
gen deposition in fibromas from patient with 
juvenile hyaline fibromatosis. J Dermatol Sci 
2009; 55: 197–200.
3. Tzellos TG, Dionyssopoulos A, Klagas I, Ka-
rakiulakis G, Lazaridis L, Papakonstantinou 
E. Differential glycosaminoglycan expression 
and hyaluronan homeostasis in juvenile hy-
aline fibromatosis. J Am Acad Dermatol 2009; 
61: 629–638.
4. Hanks S, Adams S, Douglas J, Arbour L, 
Atherton DJ, Balci S, et al. Mutations in the 
gene encoding capillary morphogenesis pro-
tein 2 cause juvenile hyaline fibromatosis and 
infantile systemic hyalinosis. Am J Hum Genet 
2003; 73: 791–800.
5. Nofal A, Sanad M, Assaf M, Nofal E, Nassar 
A, Almokadem S, et al. Juvenile hyaline fibro-
matosis and infantile systemic hyalinosis: a 
unifying term and a proposed grading system. 
J Am Acad Dermatol 2009; 61: 695–700.
6. Scobie HM, Rainey GJ, Bradley KA, Young JA. 
Human capillary morphogenesis protein 2 
functions as an anthrax toxin receptor. Proc 
Natl Acad Sci USA 2003; 100: 5170–5174.
7. Bell SE, Mavila A, Salazar R, Bayless KJ, Ka-
nagala S, Maxwell SA, et al. Differential gene 
expression during capillary morphogenesis in 
3D collagen matrices: regulated expression 
of genes involved in basement membrane 
matrix assembly, cell cycle progression, cel-
lular differentiation and G-protein signaling. 
J Cell Sci 2001; 114: 2755–2773.
8. Deuquet J, Lausch E, Guex N, Abrami L, Salvi 
S,  Lakkaraju A, et al.  Hyaline fibromatosis 
syndrome inducing mutations in the ectodomain of anthrax 
toxin receptor 2 can be rescued by proteasome inhibitors. 
EMBO Mol Med 2011; 3: 208–221.
9. Vahidnezhad H, Ziaee V, Youssefian L, Li Q, Sotoudeh S, 
Uitto J. Infantile systemic hyalinosis in an Iranian family with 
a mutation in the CMG2/ANTXR2 gene. Clin Exp Dermatol 
2015; 40: 636–639.
10. El-Kamah GY, Fong K, El-Ruby M, Afifi HH, Clements SE, 
Lai-Cheong JE, et al. Spectrum of mutations in the ANTXR2 
(CMG2) gene in infantile systemic hyalinosis and juvenile 
hyaline fibromatosis. Br J Dermatol 2010; 163: 213–215.
11. Favier R, Akshoomoff N, Mattson S, Grossfeld P. Jacobsen 
syndrome: Advances in our knowledge of phenotype and 
genotype. Am J Med Genet C Semin Med Genet 2015; 169: 
239–250.
Fig. 1. Clinical features of patients with hyaline fibromatosis syndrome. Note a tumor 
on the right parietal area (a) and multiple nuchal papules (b) in Patient 3. Patient 4 had 
extensive perianal rash with subcutaneous nodules (c). Patient 2 had characteristic findings 
of HFS, including flexural contracturs of the joints (“frog-leg position”) (f), multiple reddish 
pearly papules on the face and neck (e, g), prominent low-set ears (e), and hyperpigmentation 
shown on lateral malleoli (d).
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